ATORVASTATIN PREVENTS MEDICATION-RELATED OSTEONECROSIS OF THE JAW IN RATS
Journal
International Journal of Oral and Maxillofacial Surgery
Date Issued
2024-01
Author(s)
Koneski, F.
Monevska, D. Popovik
Popovski, V.
Kirkov, A.
Dvojakovska, S. Bozovic
Panchevski, G.
Grchev, A.
Iliev, A.
Idoska, S.
Stamatoski, A.
DOI
10.1016/j.ijom.2023.10.147
Abstract
Background: Medication-related osteonecrosis of the jaw
(MRONJ) is a serious complication of antiresorptive
drugs, that is still a subject of clinical and experimental
research. Recent studies show that statins might have a
potential positive effect on bone metabolism via stimu-
lation of osteoblastic activity.
Aim: The aim of this study is to assess the effects of
atorvastatin on the prevention of MRONJ.
Methods: Twenty-five white laboratory Wistar rats were
divided equally in five groups. Positive control group
received only saline i.p. while all other groups received
0.06 mg/kg zoledronic acid i.p., once weekly for seven
weeks, including the negative control group. In addition,
examined groups 1, 2 and 3 received a single atorvastatin
injection on the extraction site immediately after the
extraction, once weekly intraperitoneal atorvastatin in-
jection for seven weeks, and local injection of atorva-
statin two weeks after the tooth extraction, respectively.
Tooth extraction was performed in all groups on day 21.
Clinical scores of wound healing and three-dimensional
cone-beam computed tomography (CBCT) were per-
formed to evaluate the occurrence of MRONJ. Mann-
Whitney U test was used for statistical analysis and P
value of <0.05 was considered as significant.
Results: Negative control group showed significantly
impaired wound healing, with exposed necrotic bone,
confirmed with osteolytic lesions on CBCT. All groups
treated with atorvastatin showed statistically sig-
nificant improved wound healing, less osteonecrosis
and better scores on CBCT evaluation, when com-
pared to negative control group, but similar to posi-
tive control group.
Conclusion: Atorvastatin may be an option for preven-
tion and treatment of MRONJ.
(MRONJ) is a serious complication of antiresorptive
drugs, that is still a subject of clinical and experimental
research. Recent studies show that statins might have a
potential positive effect on bone metabolism via stimu-
lation of osteoblastic activity.
Aim: The aim of this study is to assess the effects of
atorvastatin on the prevention of MRONJ.
Methods: Twenty-five white laboratory Wistar rats were
divided equally in five groups. Positive control group
received only saline i.p. while all other groups received
0.06 mg/kg zoledronic acid i.p., once weekly for seven
weeks, including the negative control group. In addition,
examined groups 1, 2 and 3 received a single atorvastatin
injection on the extraction site immediately after the
extraction, once weekly intraperitoneal atorvastatin in-
jection for seven weeks, and local injection of atorva-
statin two weeks after the tooth extraction, respectively.
Tooth extraction was performed in all groups on day 21.
Clinical scores of wound healing and three-dimensional
cone-beam computed tomography (CBCT) were per-
formed to evaluate the occurrence of MRONJ. Mann-
Whitney U test was used for statistical analysis and P
value of <0.05 was considered as significant.
Results: Negative control group showed significantly
impaired wound healing, with exposed necrotic bone,
confirmed with osteolytic lesions on CBCT. All groups
treated with atorvastatin showed statistically sig-
nificant improved wound healing, less osteonecrosis
and better scores on CBCT evaluation, when com-
pared to negative control group, but similar to posi-
tive control group.
Conclusion: Atorvastatin may be an option for preven-
tion and treatment of MRONJ.
Subjects